Filing in Europe? The European Patent Office (EPO) examination process differs significantly from the United States Patent and Trademark Office (USPTO), and these differences can dramatically affect your patent strategy. What works in the U.S. may not work in Europe, and vice versa.
Whether you're an American inventor expanding to European markets, a European startup considering U.S. protection, or a multinational company managing a global patent portfolio, understanding these differences helps you make smarter filing decisions and avoid costly mistakes.
This guide breaks down the key differences between EPO and USPTO examination, including major updates to EPO guidelines that took effect in April 2026.
The Fundamental Philosophy Difference
Before diving into specific rules, it's worth understanding the philosophical difference between the two systems.
The USPTO tends to be more flexible and iterative. You can file continuation applications indefinitely, amend claims extensively, and take years to refine your patent strategy. The system assumes you'll work with the examiner over multiple rounds to reach an allowable set of claims.
The EPO is more structured and time-bound. You have limited opportunities for divisional applications, stricter timelines for amendments, and less flexibility once prosecution begins. The system expects you to have a clear strategy from the start.
Neither approach is better—they're just different. But these philosophical differences manifest in concrete procedural rules that affect how you prosecute patents.
Continuation & Divisional Applications: The Biggest Difference
This is perhaps the most significant procedural difference between the two systems, and it fundamentally shapes patent strategy.
USPTO Approach: Unlimited Flexibility
In the United States, you can file unlimited continuation and divisional applications based on a single initial filing. As long as at least one application in the family remains pending, you can continue filing new applications claiming priority to the original.
This means:
- You can keep refining claims for 10+ years
- You can file new applications as your technology evolves
- You can respond to competitor patents by filing continuations with claims designed to cover their products
- You can maintain "submarine" applications that eventually issue with claims covering mature markets
Example: You file a patent application in 2020 covering a battery technology. The examiner rejects some claims but allows others. You accept the allowed claims and file a continuation pursuing the rejected claims with amendments. That continuation gets partially allowed, so you file another continuation. Meanwhile, your technology evolves, so you file another continuation with new claims. By 2030, you have multiple issued patents and pending applications, all claiming priority to your 2020 filing.
This flexibility is powerful but can be expensive. Each continuation requires new filing fees and attorney time.
EPO Approach: Strict Time Limits
The EPO implemented Rule 36(1) EPC to prevent indefinite continuation practice. Divisional applications may only be filed if:
- The earlier application is still pending, AND
- Either:
- 24 months have not yet elapsed from the first Examination Report, OR
- 24 months have not yet elapsed from any communication objecting that the earlier application contains multiple distinct inventions (lack of unity)
Once these 24-month windows close, you cannot file further divisionals.
Example: You file a European patent application in 2024. The EPO issues its first Examination Report in January 2026, noting your application covers multiple inventions. You have until January 2028 to file divisional applications. If the examiner issues another lack-of-unity objection in June 2026, you have until June 2028 to file divisionals based on that objection. But once both windows close, you're done—no more divisionals.
Strategic Implications
The EPO's strict divisional rules require earlier commitment to claim scope. You can't wait years to see how the market develops or how competitors respond. You need to:
- Identify all potentially patentable inventions upfront
- File divisionals early if your application covers multiple inventions
- Plan your divisional strategy within the 24-month windows
- Be more conservative with claim scope in your initial filing
For multinational filings, this often means:
- Filing broader initial applications to preserve options
- Pursuing aggressive divisional strategies in Europe while maintaining flexibility in the U.S.
- Coordinating prosecution between jurisdictions to avoid inconsistent claim scope
Prosecution Timelines & Procedures
Beyond divisionals, the two systems differ in how quickly examination proceeds and how much back-and-forth is typical.
Time to First Office Action
The EPO generally issues its first Examination Report faster than the USPTO issues its first office action. EPO applications often receive substantive examination within 12-18 months of entering the examination phase, while USPTO applications average 16-24 months depending on technology area.
However, the EPO's Search Report (issued before examination) adds time upfront. You typically receive a Search Report 6-12 months after filing, then enter examination later.
Amendment Opportunities
The USPTO is more permissive with amendments. You can amend claims multiple times, introduce new dependent claims, and even add new independent claims (with restrictions). The examiner will consider your amendments and issue new office actions as needed.
The EPO is stricter about amendments, especially late in prosecution. Amendments that introduce new subject matter or broaden claim scope face scrutiny. After receiving the first Examination Report, you have limited opportunities to make substantive changes.
Oral Proceedings
The EPO offers oral proceedings (similar to examiner interviews) where you can discuss issues with the examiner. These are often productive and can resolve rejections that might otherwise require multiple written responses.
The USPTO also allows examiner interviews, but they're less formal and don't have the same procedural weight as EPO oral proceedings.
Fee Structures
Both systems charge filing fees, search fees, examination fees, and maintenance fees, but the structures differ:
- EPO fees increase significantly for claims beyond 15 and for each year you maintain the application
- USPTO fees have different tiers based on entity size (micro, small, large) and charge for extensions of time
- EPO validation fees are required in each designated country after grant, adding substantial cost
- USPTO maintenance fees are due at 3.5, 7.5, and 11.5 years after grant
For cost-conscious applicants, these fee differences can influence strategy. The EPO's per-claim fees incentivize narrower claim sets, while the USPTO's structure allows broader claim sets without penalty.
2026 EPO Guideline Updates
On April 1, 2026, the EPO implemented significant updates to its Guidelines for Examination. These changes affect how examiners evaluate novelty, interpret claims, and assess prior art.
Selection Inventions: Narrower Prior Art Scope
What changed: The EPO now applies a stricter standard for when a selected sub-range is considered disclosed by prior art.
New rule: A selected sub-range is only non-novel if the skilled person can clearly and unambiguously derive it from the prior art using common general knowledge.
Impact: This makes it easier to patent inventions that select a specific range from a broader known range, as long as the selection isn't explicitly disclosed or obvious.
Example: Prior art discloses a catalyst composition with metal content of 1-50%. Your invention claims 5-15% metal content with unexpected benefits. Under the new guidelines, this selection is more likely to be considered novel unless the prior art clearly points to the 5-15% range specifically.
This is good news for pharmaceutical, chemical, and materials science inventions where selecting specific ranges or subsets often leads to improved properties.
Marketed Products: Easier to Cite as Prior Art
What changed: The EPO clarified that commercially available products form part of the state of the art with all analyzable properties, without requiring that the product be reproducible.
New rule: If a product was publicly available before your filing date, all of its properties (including those discovered through analysis) can be cited as prior art—even if the product is no longer available or cannot be reproduced.
Impact: This makes it harder to patent inventions that merely analyze or characterize existing products. If your invention is "discovering" a property of a known product, that property is considered prior art.
Example: A competitor sold a polymer material in 2024. Your 2026 patent application claims a polymer with specific crystalline structure and thermal properties. If analysis of the competitor's 2024 product shows it has those properties, that product is prior art—even if the competitor didn't know about those properties and even if the product is no longer manufactured.
This change particularly affects:
- Reverse engineering inventions
- Analytical method patents
- Composition patents based on newly discovered properties
Claim Interpretation: Description Now Systematically Considered
What changed: Following EPO decision G 1/24, the EPO now systematically considers the description and drawings when interpreting claims in all cases, not just when claims are ambiguous.
New rule: Examiners must interpret claims in light of the description and drawings, even if the claim language seems clear on its own.
Impact: This aligns EPO practice more closely with USPTO practice and generally leads to broader claim interpretation, which can make it harder to distinguish prior art.
Example: Your claim recites "a machine learning model for patent analysis." The claim language is clear, but your description only describes convolutional neural networks. Under the new guidelines, the examiner will interpret "machine learning model" in light of your description, potentially limiting it to CNN-based approaches. This narrower interpretation might help you distinguish prior art that uses different ML architectures, but it also limits your claim scope.
Strategic implications:
- Be careful what you put in the description. Limiting statements can narrow your claims even if the claim language is broad.
- Use consistent terminology. If your claims use one term and your description uses another, examiners may interpret them as different things.
- Consider including multiple embodiments. If your description shows various implementations, your claims are less likely to be narrowly interpreted.
This change makes EPO practice more similar to USPTO practice, where the description has always been used to interpret claims. But it's a significant shift for EPO practitioners who were used to relying primarily on claim language.
Practical Implications for Inventors
How do these differences affect your patent strategy? Here's what to consider based on your filing plans.
If You're Filing in the EPO
Plan your divisional strategy early. Don't wait to see what the examiner says—identify all potentially patentable inventions upfront and be ready to file divisionals within the 24-month windows.
Expect tighter timelines. You have less flexibility to amend claims late in prosecution, so get your claims right earlier in the process.
Be mindful of marketed products. If your invention relates to analyzing or characterizing existing products, make sure you're claiming something beyond the product's inherent properties.
Watch your description carefully. With the new claim interpretation guidelines, limiting statements in your description can narrow your claims. Be precise but not unnecessarily restrictive.
Consider the 2026 changes as opportunities. The selection invention changes make it easier to patent specific ranges and subsets. Use this to your advantage if your invention involves optimizing known compositions or parameters.
If You're Filing in Both EPO and USPTO
Harmonize claims where possible. Having similar claim scope in both jurisdictions simplifies enforcement and licensing.
But recognize when divergence makes sense. The EPO's stricter divisional rules might lead you to pursue narrower claims in Europe while maintaining broader claims in the U.S.
Use the PCT route. Filing through the Patent Cooperation Treaty gives you 30-31 months to decide whether to enter national/regional phase in the EPO and USPTO. This delay lets you assess market potential and refine strategy.
Coordinate prosecution timing. If the EPO examiner finds prior art, you can use that information in your USPTO prosecution (and vice versa). Stagger your responses to learn from each jurisdiction.
Be aware of fee differences. The EPO's per-claim fees and validation costs can add up quickly. Budget accordingly.
If You're Deciding Between EPO and USPTO
Choose USPTO if:
- You want maximum flexibility to refine claims over time
- Your technology is rapidly evolving and you need to file continuations as it develops
- Your primary market is North America
- You prefer iterative prosecution with multiple amendment opportunities
Choose EPO if:
- You want faster resolution (EPO prosecution is often quicker overall)
- Your primary market is Europe
- You have a clear claim strategy from the start
- You want to avoid the cost of maintaining multiple continuation applications
File in both if:
- You have significant markets in both regions
- You can afford the additional cost
- Your invention has strong commercial potential
- You want comprehensive global protection
Many companies file in both jurisdictions through the PCT, which delays the decision and gives you time to assess market response before committing to expensive national/regional phase prosecution.
Frequently Asked Questions
Can I file divisionals in the EPO after the 24-month window closes?
No. Once both 24-month windows (from first Examination Report and from any lack-of-unity objection) have closed, you cannot file further divisionals. This is a hard deadline. Plan accordingly.
What is EPO decision G 1/24 and why does it matter?
G 1/24 is a decision by the EPO's Enlarged Board of Appeal that clarified how claims should be interpreted. It established that the description and drawings must always be considered when interpreting claims, not just when claims are ambiguous. This brings EPO practice closer to USPTO practice and generally leads to narrower claim interpretation.
Should I file in the EPO or USPTO first?
Neither—file through the PCT first. This gives you 30-31 months to decide whether to enter national/regional phase in each jurisdiction. You can use this time to assess market potential, conduct further prior art searches, and refine your strategy. The PCT route is almost always preferable for international filings.
How do the 2026 EPO changes affect pending applications?
The new guidelines apply to all pending applications, not just those filed after April 1, 2026. If your application is currently in prosecution, examiners will apply the new standards for selection inventions, marketed products, and claim interpretation. Review your pending applications to see if these changes affect your strategy.
Are EPO patents valid in all European countries?
An EPO patent is a single application that, once granted, must be validated in each designated country where you want protection. Validation involves paying fees and often translating the patent into the national language. After validation, the patent becomes a national patent in each country, subject to that country's enforcement and maintenance rules.
Which system is "better" for software patents?
Both systems have challenges for software patents. The USPTO's § 101 eligibility requirement (abstract idea doctrine) can be difficult for pure software inventions. The EPO's exclusion of "programs for computers as such" creates similar hurdles. In both systems, the key is showing a concrete technical implementation that solves a technical problem. Neither system is clearly "better"—success depends on how you frame your invention.
Conclusion
The EPO and USPTO examination systems reflect different philosophies about patent prosecution. The USPTO offers flexibility and iterative refinement over extended timelines. The EPO requires earlier strategic commitment with stricter timelines and limited divisional opportunities.
The 2026 EPO guideline updates add new considerations: selection inventions are easier to patent, marketed products are easier to cite as prior art, and claim interpretation now systematically considers the description. These changes bring EPO practice closer to USPTO practice in some ways while maintaining distinct procedural differences.
Understanding these differences helps you:
- Choose the right jurisdiction for your invention
- Plan divisional strategies that comply with EPO rules
- Draft applications that work well in both systems
- Avoid costly mistakes from assuming one system works like the other
For most inventors targeting global markets, the best strategy is filing through the PCT to preserve options, then entering national/regional phase in both the EPO and USPTO with strategies tailored to each system's requirements.
Before filing in either jurisdiction, a thorough novelty check helps you understand the prior art landscape and craft claims that will succeed under each system's rules. Get AI-powered patent analysis for 30 EUR and receive comprehensive insights on novelty, prior art, and claim structure—with secure EU processing and delivery within hours.